DiaMedica Therapeutics IncNASDAQ:DMAC
- LAST PRICE4.8100
- TODAY'S CHANGE (%)0.1900 (4.1126%)
- Bid / Lots4.8000/ 2
- Ask / Lots4.8400/ 35
- Open / Previous Close4.6800 / 4.6200
- Day Range
- 52 Week Range
- Volume49,275
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DMAC |
|---|---|---|
| 09:32 ET | 902 | 4.68 |
| 09:42 ET | 400 | 4.765 |
| 09:46 ET | 1100 | 4.765 |
| 09:48 ET | 2900 | 4.765 |
| 09:51 ET | 400 | 4.82 |
| 10:00 ET | 500 | 4.83 |
| 10:08 ET | 100 | 4.82 |
| 10:11 ET | 1000 | 4.8328 |
| 10:15 ET | 850 | 4.835 |
| 10:18 ET | 558 | 4.835 |
| 10:20 ET | 1370 | 4.835 |
| 10:22 ET | 3182 | 4.8693 |
| 10:24 ET | 114 | 4.86 |
| 10:26 ET | 2800 | 4.86 |
| 10:38 ET | 914 | 4.885 |
| 10:40 ET | 309 | 4.87 |
| 10:45 ET | 500 | 4.8605 |
| 10:47 ET | 200 | 4.86 |
| 10:49 ET | 600 | 4.8311 |
| 10:58 ET | 100 | 4.82 |
| 11:00 ET | 2905 | 4.84 |
| 11:02 ET | 200 | 4.875 |
| 11:09 ET | 100 | 4.87 |
| 11:21 ET | 100 | 4.86 |
| 11:25 ET | 100 | 4.9 |
| 11:27 ET | 3238 | 4.9095 |
| 11:34 ET | 100 | 4.89 |
| 11:38 ET | 423 | 4.88 |
| 11:39 ET | 1810 | 4.84 |
| 11:41 ET | 4041 | 4.83 |
| 11:43 ET | 100 | 4.825 |
| 11:52 ET | 487 | 4.8198 |
| 11:54 ET | 300 | 4.81 |
| 11:56 ET | 100 | 4.8 |
| 11:59 ET | 510 | 4.82 |
| 12:01 ET | 103 | 4.8 |
| 12:03 ET | 2800 | 4.828649 |
| 12:10 ET | 200 | 4.81 |
| 12:12 ET | 100 | 4.813 |
| 12:21 ET | 100 | 4.825 |
| 12:26 ET | 100 | 4.825 |
| 12:30 ET | 2607 | 4.81 |
| 12:35 ET | 3046 | 4.81 |
Nov 15, 2024
DJ Diamedica Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 6:28AM ET on Friday Nov 15, 2024 by Dow Jones
6:28AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
*DJ Diamedica Therapeutics 3Q Loss/Shr 15c >DMAC, from 4:20PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:20PM ET on Wednesday Nov 13, 2024 by Dow JonesDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results, from 4:20PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:20PM ET on Wednesday Nov 13, 2024 by Dow JonesDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference, from 8:23AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:23AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
DiaMedica Therapeutics Inc | 200.9M | -8.7x | --- |
Immutep Ltd | 312.1M | -8.4x | --- |
Acrivon Therapeutics Inc | 203.9M | -2.8x | --- |
Compass Therapeutics Inc. | 205.0M | -4.4x | --- |
Climb Bio Inc | 205.0M | -1.4x | --- |
Onkure Therapeutics Inc | 207.4M | -1.2x | --- |
Company Information
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Contact Information
- Headquarters
- 301 CARLSON PARKWAY, SUITE 210MINNEAPOLIS, MN, United States 55305
- Phone
- 763-496-5454
- Fax
- 763-710-4456
Executives
- Independent Chairman of the Board
- Richard Pilnik
- President, Chief Executive Officer, Director
- Rick Pauls
- Chief Financial Officer, Company Secretary
- Scott Kellen
- Chief Technology Officer
- Ambarish Shah
- Chief Commercial Officer
- Dominic Cundari
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $200.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 42.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-0.55 |
Book Value | $1.35 |
P/E Ratio | -8.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
